Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial

被引：12
|
作者：
Ryan, P. D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Neven, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Blackwell, K. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Dirix, L. Y. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Barrios, C. H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Miller, W. H., Jr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Fein, L. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Fenton, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Benner, R. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Meech, S. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Paccagnella, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Sleight, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Yee, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Goss, P. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Univ Ziekenhuis Leuven, Leuven, Belgium
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Sint Augustinus, Oncol Ctr, Antwerp, Belgium
[5] PUCRS Sch Med, Porto Alegre, RS, Brazil
[6] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
[7] Ctr Oncol Rosario, Santa Fe, Argentina
[8] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[9] Pfizer Inc, Groton, CT 06340 USA
[10] Univ Minnesota, Minneapolis, MN USA
[11] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P1-17-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-17-01
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer
    Hasenburg, A.
    van de Velde, C. J. H.
    Seynaeve, C.
    Rea, D. W.
    Vannetzel, J.
    Paridaens, R.
    Markopoulos, C.
    Hozumi, Y.
    Putter, H.
    Jones, S. E.
    EJC SUPPLEMENTS, 2010, 8 (03): : 62 - 62
  • [32] A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer
    Freedman, O. C.
    Amir, E.
    Dranitsaris, G.
    Dowsett, M.
    Cole, D. E. C.
    Kahn, H.
    O'Malley, F.
    Verma, S.
    Clemons, M.
    BREAST CANCER RESEARCH, 2009, 11 : S20 - S20
  • [33] A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer
    OC Freedman
    E Amir
    G Dranitsaris
    M Dowsett
    DEC Cole
    H Kahn
    F O'Malley
    S Verma
    M Clemons
    Breast Cancer Research, 11
  • [34] Cost-effectiveness of everolimus plus exemestane in postmenopausal hormone receptor positive metastatic breast cancer
    Zeichner, Simon B.
    Avancha, Kiran Kumar Venkata Raja
    Lopes, Gilberto
    Gluck, Stefan
    Montero, Alberto J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer A Randomized Clinical Trial
    Serrano, Davide
    Gandini, Sara
    Thomas, Parjhitham
    Crew, Katherine D.
    Kumar, Nagi B.
    Vornik, Lana A.
    Lee, J. Jack
    Veronesi, Paolo
    Viale, Giuseppe
    Guerrieri-Gonzaga, Aliana
    Lazzeroni, Matteo
    Johansson, Harriet
    D'Amico, Mauro
    Guasone, Flavio
    Spinaci, Stefano
    Bertelsen, Bjorn-Erik
    Mellgren, Gunnar
    Bedrosian, Isabelle
    Weber, Diane
    Castile, Tawana
    Dimond, Eileen
    Heckman-Stoddard, Brandy M.
    Szabo, Eva
    Brown, Powel H.
    DeCensi, Andrea
    Bonanni, Bernardo
    JAMA ONCOLOGY, 2023, 9 (05) : 664 - 672
  • [36] Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer
    Sendur, Mehmet Ali Nahit
    Aksoy, Sercan
    Akinci, Muhammed Bulent
    Ozdemir, Nuriye
    Dede, Didem Sener
    Altundag, Kadri
    Zengin, Nurullah
    Yalcin, Bulent
    FUTURE ONCOLOGY, 2015, 11 (06) : 905 - 907
  • [37] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
    Bergh, Jonas
    Jonsson, Per-Ebbe
    Lidbrink, Elisabet Kerstin
    Trudeau, Maureen
    Eiermann, Wolfgang
    Brattstrom, Daniel
    Lindemann, Justin P. O.
    Wiklund, Fredrik
    Henriksson, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1919 - 1925
  • [38] Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)
    Takei, Hiroyuki
    Suemasu, Kimito
    Inoue, Kenichi
    Saito, Tsuyoshi
    Okubo, Katsuhiko
    Koh, Junichi
    Sato, Kazuhiko
    Tsuda, Hitoshi
    Kurosumi, Masafumi
    Tabei, Toshio
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 107 (01) : 87 - 94
  • [39] Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)
    Hiroyuki Takei
    Kimito Suemasu
    Kenichi Inoue
    Tsuyoshi Saito
    Katsuhiko Okubo
    Junichi Koh
    Kazuhiko Sato
    Hitoshi Tsuda
    Masafumi Kurosumi
    Toshio Tabei
    Breast Cancer Research and Treatment, 2008, 107 : 87 - 94
  • [40] Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis
    Xu, Liang
    Jiang, Weifan
    Li, Wenwei
    Guo, Chungen
    Luo, Lihua
    Gao, Yufeng
    Cao, Yali
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (03)
12345